Seelos Therapeutics to Participate in Upcoming Investor Conference in September

NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies. The company will host One on One meetings in New York, NY on Monday, September 23rd and Tuesday, September 24th.

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information: Anthony Marciano Head of Corporate Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park Ave., 12th Fl New York, NY 10022 (646) 293-2136 [email protected] www.seelostherapeutics.com https://twitter.com/seelostx https://www.linkedin.com/company/seelos

You May Also Be Interested In

• SuperiorMed Holdings Limited Announces Entering into an Agreement and Plan of Merger with Starry Sea Acquisition Corp
• Altus Launches Public Beta: 24/5 U.S. Stock Trading, Funded with USDC on Solana
• Dr. Christina Asare Advances Cybersecurity Strategy and AI Governance Leadership Through Growing Consulting Portfolio